# CLINICAL AND EXPERIMENTAL VACCINE RESEARCH Check for chipdates

Clin Exp Vaccine Res 2023;12:134-142 https://doi.org/10.7774/cevr.2023.12.2.134 pISSN 2287-3651 • eISSN 2287-366X

# Osman Samet Gunkaya<sup>1</sup>, Arzu Bilge Tekin<sup>1</sup>, Murat Yassa<sup>2</sup>, Oguz Arslan<sup>1</sup>, Kübra Karakoç<sup>1</sup>, Nesibe Demirtaş<sup>1</sup>, Canberk Usta<sup>1</sup>, Çiğdem Künt İşgüder<sup>1</sup>, Niyazi Tuğ<sup>1</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital, University of Health Sciences Turkey, Istanbul; <sup>2</sup>Clinic of Obstetrics and Gynecology, VM Medical Park Maltepe Hospital, Istanbul, Turkey

Received: December 24, 2022 Revised: January 31, 2023 Accepted: February 5, 2023

Corresponding author: Osman Samet Gunkaya, MD Department of Obstetrics and Gynecology, Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital, University of Health Sciences Turkey, Namik Kemal Cd. No:7, 34785 Sancaktepe, Istanbul, Turkey

Tel: +90-507-650-3540, Fax: +90-216-606-3300 E-mail: dr.sametgunkaya@hotmail.com

No potential conflict of interest relevant to this article was reported.



#### © Korean Vaccine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

# Pregnant women's knowledge about and beliefs toward COVID-19 vaccine: a cross-sectional study

**Purpose:** The aim of this study was to determine the scope of knowledge, attitudes, and behaviors of pregnant women about the coronavirus disease 2019 (COVID-19) vaccine.

**Materials and Methods:** A total of 886 pregnant women were recruited for the study. A cross-sectional questionnaire was conducted on these selected participants. Data about past infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV-2 infection of closely related people, and deaths due to COVID-19 among their relatives were questioned.

**Results:** The rate of vaccination was higher (64.1%) in pregnant women with higher education levels. Informing about the vaccine, especially by health professionals, showed that the rates of vaccination (25%) increased (p<0.001). In addition, a significant increase was observed in vaccination rates with increasing age and financial income (p<0.001).

**Conclusion:** The main limitation of our study is that the vaccine, which was approved for "emergency use", was just started to be administered to pregnant women during the study. Our findings show that our target audience, low-income, low-education, younger pregnant women should be given more attention than those who apply to the doctor for routine follow-up.

Keywords: COVID-19 vaccine, Pandemics, Pregnant

#### Introduction

The coronavirus disease 2019 (COVID-19) pandemic has quarantined billions of people, exacerbating pre-existing psychological and health problems and affecting various aspects of life, and it has caused a challenge to health systems, the economy, and education [1-4]. The effectiveness of vaccines against viral infections is known [5]. Assuming the baseline reproduction number is 4, the population immunity level needs to reach at least 70% to stop the COVID-19 pandemic [6]. Therefore, vaccines cannot prevent epidemics without widespread acceptance. The World Health Organization has listed vaccine hesitancy as one of the top ten threats to global health [7]. Vaccine hesitancy is one of the most significant public health challenges facing efforts to manage the coronavirus disease 2019 (COVID-19) pandemic globally [8].

Pregnant women are considered a vulnerable and at-risk population for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [9]. If infected, they have more risk of developing complications such as intensive care unit admission, mechanical ventilation, and death [10,11]. In addition, increased risk of miscarriage, iatrogenic preterm delivery, preeclampsia, cesarean section, and postpartum hemor-

## Osman Samet Gunkaya et al • Attitude of pregnant women to COVID-19 vaccine

rhage, have also been reported [12-14].

The results and reliability of vaccine studies in pregnant women started to become clear in the second half of 2021 [15,16]. Pregnant women are the ones who can influence a decision on vaccine acceptance of children and other family members. Understanding the factors that influence vaccination acceptance across diverse socioeconomic groups, particularly pregnant women, is critical to restoring society to pre-pandemic conditions [17].

In this context, we aimed to investigate the scope of knowledge, attitudes, and behaviors of pregnant women about the COVID-19 vaccine in our study.

#### **Materials and Methods**

#### Study design

This study was conducted by simple random sampling from pregnant women who applied to the gynecology outpatient clinic in a tertiary center in Istanbul, Turkey, between October 1, 2021, and December 1, 2021. The study included those who are currently pregnant (without distinction of trimester), have no contraindications to the vaccine, have access to the vaccine, and want to participate voluntarily. Survey questions were taken from previous studies conducted for similar purposes [18]. A cross-sectional questionnaire was conducted on these selected participants. Before the interviews, the participants were informed about the study and the confidentiality of the interview, and for those who did not want to answer only one question of the survey, the other questions of the survey were not continued. In the first part of the questionnaire, the socio-demographic characteristics of the pregnant women (age, educational status, pregnancy history, current gestational week, and monthly income levels, data about past infection with SARS-CoV-2, SARS-CoV-2 infection of closely related people, and deaths due to COVID-19 among their relatives) were questioned. While the illiterates read and answered the questionnaires, the participants were informed about the purpose of the study and data privacy.

Studies measuring vaccination hesitancy were sought for the purpose of calculating sample size. A study conducted on pregnant women in the United States found that the vaccination delay rate was 8.2% [19], and in a study of pregnant women in Malaysia, it was 11.6% [20]. The study sample size was calculated using the sampling method. This led to an unknown population [21] and an accepted 11% vaccine skepticism.

$$n = \frac{t^2 \times (p \times q)}{d^2}$$

n: sample size

p: frequency of incidence of the event under consideration (expected prevalence)

q: frequency of absence of the event under consideration (expected non-prevalence)

t: the standard normal deviate (usually set at 1.96, which corresponds to the 95% confidence interval)

d: relative desired precision [13].

$$\frac{(1.96)^2 \times (0.11 \times 0.89)}{(0.05)^2} = 150$$

It was determined that at least 150 pregnant women should be included in the study.

#### Surveys

The questionnaire was developed based on the content of questionnaire tools used in pregnant women vaccinated against influenza by some of us recording different populations [18]. The questionnaire was tested among 10 unselected women to assess comprehension of the questions and answers. Pretest participants were not included in the results.

Level of knowledge about the COVID-19 vaccine

Survey questions: "COVID-19 is severe during pregnancy." "The vaccine also protects pregnant women from COVID-19." "All COVID-19 vaccines can be applied to pregnant women." "The COVID-19 vaccine during pregnancy causes disease in the fetus." "The COVID-19 vaccine during pregnancy causes preterm delivery/abortus." The answer options are "yes," "no," and "don't know."

Information source about COVID-19 and the vaccine

Survey questions: "Were you informed about COVID-19 during pregnancy?" "Were you informed about the COVID-19 vaccine during pregnancy?" The answers of these questions are "no," "doctor/nurse," "media," "friends," "family," and "others." The remaining survey questions are "Would you like to receive information about COVID-19?" "Would you like to learn about the COVID-19 vaccine?" The answers to these questions are "yes" and "no."

The reason for getting or not getting vaccinated against COVID-19

Those who answered "no": "I do not have risk." "The vaccine

## CLINICAL AND EXPERIMENTAL VACCINE RESEARCH

Osman Samet Gunkaya et al • Attitude of pregnant women to COVID-19 vaccine

can be harmful to my health." "I do not believe in the benefit." "My doctor was against." "Other." Those who answered "yes": "I belong to the risk group." "The vaccine is not harmful to my health." "The vaccine is not harmful to the health of my baby." "I believe in the benefit." "My doctor recommended." "Other."

#### Claims causing vaccine rejection

Survey questions: "The vaccines contain mercury, aluminum, ether and many chemicals that can cause different diseases." "The vaccine-producing companies have created a malicious market to generate revenue." "A better immunity can be gained by undergoing the disease rather than being vaccinated." "Complementary and alternative medicine is more effective and has fewer side effects." "There are no studies proving the efficacy and safety of vaccines." "There are studies reporting the side effects of vaccines." "Some people who have gained religious and philosophical activity and doctors explain that the vaccine is harmful and they do not have it done." All answer options are "yes," "no," and "don't know."

#### **Ethical considerations**

All patients gave written informed consent and were approved for publication before data collection. All procedures were in accordance with the 1964 Helsinki Declaration and its later amendments. This study followed the principles of the Declaration of Helsinki and the local institutional administration board approved the study (meeting 08/09/2021; registry no., 2021/190).

## Statistical analysis

Data analysis was performed with IBM SPSS ver. 26.0 (IBM Corp., Armonk, NY, USA). Normal distributions for continuous variables were checked using P-P plots and single-sample Kolmogorov-Smirnov tests. Comparisons between pregnant women who received the COVID-19 vaccine and those who refused the vaccine were made using chi-square tests for categorical variables, independent samples chi-square test, and Mann-Whitney U tests for continuous variables. The significant statistical difference was determined as 0.05.

#### **Results**

A total of 900 pregnant women were invited to participate in this survey, 868 met the study entry criteria and volunteered to be evaluated, and the participation rate was 96.4%. Of the

**Table 1.** Demographic characteristics of pregnant women with and without COVID-19 vaccine

No. of participants         779 (89.7)         89 (10.3)           Age (yr)         <0.001           Mean±SD         27.4±5.3         29.8±5.6           Median±IQR (min-max)         27±7 (16-44)         29±7 (19-42)           Gestational age (wk)         0.016           Mean±SD         31.6±9.2         30.0±8.8           Median±IQR (min-max)         36±2 (5-42)         33±13 (7-40)           Parity         0.246           Median±IQR (min-max)         1±2 (0-6)         1±1 (0-4)           Trimester         1         1           1 Trimester         58 (7.4)         6 (6.7)           2 Trimester         143 (18.4)         21 (23.6)           3 Trimester         578 (74.2)         62 (69.7)           Education         361 (46.3)         57 (64.1)           Secondary education         418 (53.7)         32 (35.9)           High school and higher education         361 (46.3)         57 (64.1)           Income         <0.002           Low-medium wages         750 (96.3)         78 (87.6)           High wages         29 (3.7)         11 (12.4)           Infected with SARS-CoV-2 before the vaccine recommendation         499 (64.1)         59 (66.3)           No	Characteristic	Unvaccinated	Vaccinated	p-value
Age (yr)         27.4±5.3         29.8±5.6            Median±IQR (min-max)         27±7 (16-44)         29±7 (19-42)            Gestational age (wk)         0.016         0.016           Mean±SD         31.6±9.2         30.0±8.8         0.246           Median±IQR (min-max)         1±2 (0-6)         1±1 (0-4)         0.246           Parity         0.246         0.246           Median±IQR (min-max)         1±2 (0-6)         1±1 (0-4)         1           Trimester         58 (7.4)         6 (6.7)         1           2 Trimester         143 (18.4)         21 (23.6)         3         1         1         1         1         1         1         1         1         1         1         1         1         1         1         2         (66.7)         2         1         2         1         1         1         1         1         1         1         1         1         1         1         1         1         1         2         1         2         1         2         1         2         1         2         1         2         1         2         1         2         1         2         1         2 <td>No. of participants</td> <td>779 (89.7)</td> <td>89 (10.3)</td> <td></td>	No. of participants	779 (89.7)	89 (10.3)	
Median±IQR (min-max)         27±7 (16-44)         29±7 (19-42)           Gestational age (wk)         0.016           Mean±SD         31.6±9.2         30.0±8.8           Median±IQR (min-max)         36±2 (5-42)         33±13 (7-40)           Parity         0.246           Median±IQR (min-max)         1±2 (0-6)         1±1 (0-4)           Trimester         58 (7.4)         6 (6.7)           2 Trimester         143 (18.4)         21 (23.6)           3 Trimester         578 (74.2)         62 (69.7)           Education         418 (53.7)         32 (35.9)           Secondary education         418 (53.7)         32 (35.9)           High school and higher education         361 (46.3)         57 (64.1)           Income         <0.002				< 0.001
Gestational age (wk)       31.6±9.2       30.0±8.8         Mean±SD       31.6±9.2       30.0±8.8         Median±IQR (min-max)       36±2 (5-42)       33±13 (7-40)         Parity       0.246         Median±IQR (min-max)       1±2 (0-6)       1±1 (0-4)         Trimester       58 (7.4)       6 (6.7)         2 Trimester       143 (18.4)       21 (23.6)         3 Trimester       578 (74.2)       62 (69.7)         Education       <0.001	Mean±SD	27.4±5.3	29.8±5.6	
Mean±SD       31.6±9.2       30.0±8.8         Median±IQR (min-max)       36±2 (5-42)       33±13 (7-40)         Parity       0.246         Median±IQR (min-max)       1±2 (0-6)       1±1 (0-4)         Trimester       58 (7.4)       6 (6.7)         2 Trimester       143 (18.4)       21 (23.6)         3 Trimester       578 (74.2)       62 (69.7)         Education       418 (53.7)       32 (35.9)         Secondary education       418 (53.7)       32 (35.9)         High school and higher education       361 (46.3)       57 (64.1)         Income       < 0.002         Low-medium wages       750 (96.3)       78 (87.6)         High wages       29 (3.7)       11 (12.4)         Infected with SARS-CoV-2 before the vaccine recommendation       29 (37.7)       11 (12.4)         Yes       201 (25.8)       26 (29.2)       0.6772         Yes       499 (64.1)       59 (66.3)       0.6772         Yes       499 (64.1)       59 (66.3)       0.200         Yes       671 (86.1)       81 (91.1)       0.200         Yes       671 (86.1)       81 (91.1)       0.200         Yes       671 (86.1)       81 (91.1)       0.001	Median ± IQR (min-max)	27±7 (16-44)	29±7 (19-42)	
Median±IQR (min-max)         36±2 (5-42)         33±13 (7-40)           Parity         0.246           Median±IQR (min-max)         1±2 (0-6)         1±1 (0-4)           Trimester         58 (7.4)         6 (6.7)           2 Trimester         58 (7.4)         6 (6.7)           2 Trimester         143 (18.4)         21 (23.6)           3 Trimester         578 (74.2)         62 (69.7)           Education         <0.001	Gestational age (wk)			0.016
Parity         0.246           Median±IQR (min-max)         1±2 (0-6)         1±1 (0-4)           Trimester         1           1 Trimester         58 (7.4)         6 (6.7)           2 Trimester         143 (18.4)         21 (23.6)           3 Trimester         578 (74.2)         62 (69.7)           Education         <0.001	Mean±SD	31.6±9.2	$30.0 \pm 8.8$	
Median±IQR (min-max)         1±2 (0-6)         1±1 (0-4)           Trimester         1           1 Trimester         58 (7.4)         6 (6.7)           2 Trimester         143 (18.4)         21 (23.6)           3 Trimester         578 (74.2)         62 (69.7)           Education         <0.001	Median ± IQR (min-max)	36±2 (5-42)	33±13 (7-40)	
Trimester 58 (7.4) 6 (6.7) 2 Trimester 58 (7.4) 6 (6.7) 2 Trimester 143 (18.4) 21 (23.6) 3 Trimester 578 (74.2) 62 (69.7)  Education <	Parity			0.246
1 Trimester 58 (7.4) 6 (6.7) 2 Trimester 143 (18.4) 21 (23.6) 3 Trimester 578 (74.2) 62 (69.7)  Education <	Median ± IQR (min-max)	1±2 (0-6)	1 ± 1 (0-4)	
2 Trimester 143 (18.4) 21 (23.6) 3 Trimester 578 (74.2) 62 (69.7) Education < 0.001 Secondary education 418 (53.7) 32 (35.9) High school and higher education 361 (46.3) 57 (64.1) Income < 0.002 Low-medium wages 750 (96.3) 78 (87.6) High wages 29 (3.7) 11 (12.4) Infected with SARS-CoV-2 before the vaccine recommendation Yes 201 (25.8) 26 (29.2) No 578 (74.2) 63 (70.8) Relative infected with SARS-CoV-2 499 (64.1) 59 (66.3) No 280 (35.9) 30 (33.7) Relative died due to COVID-19 Yes 671 (86.1) 81 (91.1) No 108 (13.9) 8 (8.9) Had routine vaccinations other than the COVID-19 vaccine Yes 151 (19.4) 38 (42.7)	Trimester			1
3 Trimester       578 (74.2)       62 (69.7)         Education       < 0.001	1 Trimester	58 (7.4)	6 (6.7)	
Education         < 0.001           Secondary education         418 (53.7)         32 (35.9)           High school and higher education         361 (46.3)         57 (64.1)           Income         < 0.002	2 Trimester		21 (23.6)	
Secondary education       418 (53.7)       32 (35.9)         High school and higher education       361 (46.3)       57 (64.1)         Income       < 0.002	3 Trimester	578 (74.2)	62 (69.7)	
High school and higher education       361 (46.3)       57 (64.1)         Income       < 0.002	Education			< 0.001
Income       <0.002	Secondary education	418 (53.7)	32 (35.9)	
Low-medium wages 750 (96.3) 78 (87.6) High wages 29 (3.7) 11 (12.4)  Infected with SARS-CoV-2 before the vaccine recommendation Yes 201 (25.8) 26 (29.2) No 578 (74.2) 63 (70.8)  Relative infected with SARS-CoV-2 Yes 499 (64.1) 59 (66.3) No 280 (35.9) 30 (33.7)  Relative died due to COVID-19 Yes 671 (86.1) 81 (91.1) No 108 (13.9) 8 (8.9)  Had routine vaccinations other than the COVID-19 vaccine Yes 151 (19.4) 38 (42.7)	High school and higher education	361 (46.3)	57 (64.1)	
High wages       29 (3.7)       11 (12.4)         Infected with SARS-CoV-2 before the vaccine recommendation       0.488         Yes       201 (25.8)       26 (29.2)         No       578 (74.2)       63 (70.8)         Relative infected with SARS-CoV-2       0.6772         Yes       499 (64.1)       59 (66.3)         No       280 (35.9)       30 (33.7)         Relative died due to COVID-19       0.200         Yes       671 (86.1)       81 (91.1)         No       108 (13.9)       8 (8.9)         Had routine vaccinations other than the COVID-19 vaccine       <0.001	Income			< 0.002
Infected with SARS-CoV-2 before the vaccine recommendation Yes 201 (25.8) 26 (29.2) No 578 (74.2) 63 (70.8)  Relative infected with SARS-CoV-2 Yes 499 (64.1) 59 (66.3) No 280 (35.9) 30 (33.7)  Relative died due to COVID-19 Yes 671 (86.1) 81 (91.1) No 108 (13.9) 8 (8.9)  Had routine vaccinations other than the COVID-19 vaccine Yes 151 (19.4) 38 (42.7)	Low-medium wages	750 (96.3)	78 (87.6)	
the vaccine recommendation Yes 201 (25.8) 26 (29.2) No 578 (74.2) 63 (70.8)  Relative infected with SARS-CoV-2 Yes 499 (64.1) 59 (66.3) No 280 (35.9) 30 (33.7)  Relative died due to COVID-19 Yes 671 (86.1) 81 (91.1) No 108 (13.9) 8 (8.9)  Had routine vaccinations other than the COVID-19 vaccine Yes 151 (19.4) 38 (42.7)	High wages	29 (3.7)	11 (12.4)	
Yes       201 (25.8)       26 (29.2)         No       578 (74.2)       63 (70.8)         Relative infected with SARS-CoV-2       0.6772         Yes       499 (64.1)       59 (66.3)         No       280 (35.9)       30 (33.7)         Relative died due to COVID-19       0.200         Yes       671 (86.1)       81 (91.1)         No       108 (13.9)       8 (8.9)         Had routine vaccinations other than the COVID-19 vaccine       <0.001	Infected with SARS-CoV-2 before			0.488
No       578 (74.2)       63 (70.8)         Relative infected with SARS-CoV-2       0.6772         Yes       499 (64.1)       59 (66.3)         No       280 (35.9)       30 (33.7)         Relative died due to COVID-19       0.200         Yes       671 (86.1)       81 (91.1)         No       108 (13.9)       8 (8.9)         Had routine vaccinations other than the COVID-19 vaccine       <0.001	the vaccine recommendation			
Relative infected with SARS-CoV-2 Yes	Yes	201 (25.8)	26 (29.2)	
Yes       499 (64.1)       59 (66.3)         No       280 (35.9)       30 (33.7)         Relative died due to COVID-19       0.200         Yes       671 (86.1)       81 (91.1)         No       108 (13.9)       8 (8.9)         Had routine vaccinations other than the COVID-19 vaccine       <0.001		578 (74.2)	63 (70.8)	
No       280 (35.9)       30 (33.7)         Relative died due to COVID-19       0.200         Yes       671 (86.1)       81 (91.1)         No       108 (13.9)       8 (8.9)         Had routine vaccinations other than the COVID-19 vaccine       <0.001	Relative infected with SARS-CoV-2			0.6772
Relative died due to COVID-19       0.200         Yes       671 (86.1)       81 (91.1)         No       108 (13.9)       8 (8.9)         Had routine vaccinations other than the COVID-19 vaccine       <0.001	Yes			
Yes       671 (86.1)       81 (91.1)         No       108 (13.9)       8 (8.9)         Had routine vaccinations other than the COVID-19 vaccine       < 0.001         Yes       151 (19.4)       38 (42.7)		280 (35.9)	30 (33.7)	
No         108 (13.9)         8 (8.9)           Had routine vaccinations other than the COVID-19 vaccine         <0.001	Relative died due to COVID-19			0.200
Had routine vaccinations other than the COVID-19 vaccine Yes 151 (19.4) 38 (42.7)		, ,	, ,	
the COVID-19 vaccine Yes 151 (19.4) 38 (42.7)		108 (13.9)	8 (8.9)	
				< 0.001
No 628 (80.6) 51 (57.3)	Yes	151 (19.4)	38 (42.7)	
	No	628 (80.6)	51 (57.3)	

Values are presented as number (%), mean  $\pm$  SD, or median  $\pm$  IQR (min–max). Statistically significant results are marked in bold.

SD, standard deviation; IQR, interquartile range; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

participants, 89.7% (n=779) were unvaccinated and 10.3% (n=89) were vaccinated. The age, gestational age, and parity of all pregnant women were  $27\pm7$  years,  $36\pm11$  weeks, and  $1\pm2$  (median±interquartile range), respectively. The demographic characteristics of the participants who were separated according to their COVID-19 vaccination status are presented in Table 1. Thirty-seven (4.3%) illiterate pregnant women did not want to be vaccinated and were not vaccinated.

Knowledge level of pregnant women about COVID-19 and




Fig. 1. (A-D) Knowledge level of pregnant women about coronavirus disease 2019 (COVID-19) and COVID-19 vaccine.

COVID-19 vaccine is summarized in Fig. 1. Reasons for COVID-19 vaccine acceptance and refusal are summarized in Fig. 2. Pregnant women's knowledge and willingness towards COVID-19 vaccine is summarized in Fig. 3. The rate of vaccination for the pregnant women who received information from health professionals (doctor, nurse) was 25% (39/156) and for the pregnant women who received information other than health professionals was 6.4% (34/532) (p<0.001). The distribution of claims that caused vaccine rejection is given in Table 2.

#### **Discussion**

This study found significant gaps in the knowledge of preg-

nant women about vaccination. The main concern was that the vaccine may have adverse effects on the fetus, it is important in terms of correcting the hesitations and disinformation of the pregnant women who did not get vaccinated. Almost only one woman in ten women was vaccinated in this study.

The rate of vaccination was higher (64.1%) in pregnant women with higher education levels, who had the potential to have more information about the risk level and the right source from the participants. Informing about the vaccine, especially by health professionals, showed that the rates of vaccination (25%) increased (p<0.001). In addition, a significant increase was observed in vaccination rates with increasing age and financial income (p<0.001).

The safety of the COVID-19 vaccine was proven and al-




Fig. 2. (A, B) Reasons of coronavirus disease 2019 (COVID-19) vaccine acceptance and opposition.

Table 2. Allegations leading to vaccine denial

	Yes	No	I do not know
Vaccines contain mercury, aluminum, ether, and many chemicals that can cause different diseases.	172 (22.1)	67 (8.65)	540 (69.3)
Vaccine-producing companies have created a malicious market to generate revenue.	171 (22.0)	129 (16.6)	479 (61.5)
A better immunity can be provided by passing the disease rather than being vaccinated.	148 (19.0)	162 (20.8)	469 (60.2)
Complementary and alternative medicine is more effective and has fewer side effects.	98 (12.6)	118 (15.1)	563 (72.3)
There are no studies proving the efficacy and safety of vaccines	199 (25.5)	107 (13.7)	473 (60.7)
There are studies reporting the side effects of vaccines.	263 (33.8)	67 (8.6)	449 (57.6)
Some "people who have gained religious and philosophical activity" and "doctors" explain that the vaccine is harmful and they do not have it done.	166 (21.3)	131 (16.8)	482 (61.9)

Values are presented as number (%).

though it was recommended to pregnant women, acceptance of the COVID-19 vaccine was similar to other vaccines (influenza vaccine, tetanus vaccine, etc.) [22,23]. This indicates that vaccine hesitancy is a growing public health problem in the world in the last 10 years [24].

The first encounter of pregnant women with a pandemic that affects the whole world as well as the use of the COVID-19 vaccine for the first time in the world might have caused con-

cerns about the vaccine in pregnant women. While 65.9% (n=513) of unvaccinated pregnant women think that the vaccine is harmful to the baby, 53.8% (n=47) of vaccinated pregnant women believe that the vaccine is protective against COVID-19, only 14.6% (n=13) know that they are in the risky group. These rates show that they do not have enough information about the vaccine and that the information is learned from the wrong source. Information pollution in the visual




Fig. 3. (A-D) Pregnant women knowledge and willingness towards coronavirus disease 2019 (COVID-19) vaccine.

and written media on the SARS-CoV-2 epidemic should be avoided, and it was recommended that only health professionals should provide information [25,26].

The higher the education level, the less likely they are to refuse the vaccine, as they have more information about disease risk, side effects, and efficacy [27]. In our study, vaccination rates increase with the increase in education levels. Likewise, pregnant women with a higher level of education are more likely to reach the right source of information, so the level of knowledge depends on many factors, however, the results of the survey revealed that the sources of information have an important role. It is worrying that 54.3% (n=472) of pregnant women do not have information about the severity of COV-ID-19, while 65.1% (n=565) do not have any information about vaccines. It is quite interesting that the majority of pregnant women did not see health professionals, the most frequently consulted source, as an important source of informa-

tion. Whereas health professionals are in the best position to answer questions, they have the responsibility to recommend vaccines and answer questions that come to mind. It is supported by the results that obtaining information from doctors or other health professionals is positively associated with vaccination. Pregnant women with incorrect and insufficient information are more likely to think that the COVID-19 vaccines recommended during pregnancy during the SARS-CoV-2 pandemic are dangerous for them and the unborn child. In particular, physicians informing the public about vaccination within the scope of their preventive medicine responsibilities also create an opportunity to reduce health costs. The vaccine was free at the time of study and in our country, the rate of vaccination in pregnant women in our study was found to be very low, at 10.3% (n=89). In addition, although the vaccine is free, the vaccination rate of young and low-income people was low. The reason for this may be the positive relationship be-

# CLINICAL AND EXPERIMENTAL VACCINE RESEARCH

Osman Samet Gunkaya et al • Attitude of pregnant women to COVID-19 vaccine

tween income status and education status or access to sufficient and correct information. Skirrow et al. reported that lower-income women were less likely to prefer vaccination and lower income can link to lower education levels as well as vaccine hesitancy has been linked to lower education levels [28].

COVID-19 vaccine hesitancy is a multifaceted phenomenon [29]. In another study, the main reasons participants did not want to receive the COVID-19 vaccine were the initiation of vaccination with the Emergency Use Authorization and a significant proportion of pregnant women expressed additional safety concerns due to insufficient clinical evidence [30]. In a study, Hosokawa et al. [31] reported 13.4% vaccine acceptance in pregnant women and they stated that to reduce vaccine hesitancy, accurate information transmission and increased trust in the government may be necessary. In our study, 69.3% (n=540) of pregnant women who refused the vaccine did not show any reason, while 25.5% (n=199) of them expressed that vaccine studies were insufficient and they want to see more safety and efficacy data. Although, the data about the vaccine effectiveness and safety were relatively clear at the time of the current study when compared to the beginning of the pandemic, there may still be suspicion about vaccine usage in pregnancy or a failure to transmit information about vaccine safety to the public [15,16]. As more data become available and if the transfer of this data to the public is more effective, there will be more opportunities for pregnant women to rely on scientific validation of vaccines, which may positively impact pregnant women with vaccine hesitancy and reluctance.

The time frame of the study was the main limitation of our study, lack of information about the use of vaccines for pregnant women led to the lack of confidence in policymakers, health workers, and vaccine providers and our country has given "emergency clearance" to vaccine use at the beginning of January 2021. Moreover, the methodological limitations of this research are primarily that this survey was conducted using a cross-sectional design and therefore this precludes any conclusions about causality in the relationships found between the estimators and the outcomes of interest. Second, the findings of the survey cannot be fully generalized for the Turkish pregnant female population as it was conducted in only one geographic region. Third, participants may have responded in a socially desirable manner regarding a positive attitude towards the vaccine, even though they were informed that the interview was fully confidential. Therefore, the findings are likely to be true. Despite these limitations, the survey provides useful data on this sensitive issue for policymakers and healthcare professionals.

Vaccination rates among pregnant women in the research group were found to be extremely low. Lack of knowledge about the safety of the vaccine is the biggest obstacle to vaccination. Our findings show that the recommendations of health professionals and other authorities are widespread and that low-income, low-education, young pregnant women, who are our target audience, should be given more attention than those who apply to a doctor for routine follow-up. Public awareness of the COVID-19 pandemic and vaccines should be increased through focused interventions to increase vaccine acceptance in pregnant women.

#### **ORCID**

Osman Samet Gunkaya https://orcid.org/0000-0002-2188-2503
Arzu Bilge Tekin https://orcid.org/0000-0001-8054-2624
Murat Yassa https://orcid.org/0000-0001-8661-1192
Oguz Arslan https://orcid.org/0000-0003-4014-4511
Kübra Karakoç https://orcid.org/0000-0003-2916-4538
Nesibe Demirtaş https://orcid.org/0000-0001-8182-4412
Canberk Usta https://orcid.org/0000-0002-0825-2355
Çiğdem Künt İşgüder https://orcid.org/0000-0002-0420-1913
Niyazi Tuğ https://orcid.org/0000-0001-7442-834X

#### References

- Sidor A, Rzymski P. Dietary choices and habits during COVID-19 lockdown: experience from Poland. Nutrients 2020:12:1657.
- Prati G, Mancini AD. The psychological impact of COV-ID-19 pandemic lockdowns: a review and meta-analysis of longitudinal studies and natural experiments. Psychol Med 2021;51:201-11.
- 3. Lenzen M, Li M, Malik A, et al. Global socio-economic losses and environmental gains from the coronavirus pandemic. PLoS One 2020;15:e0235654.
- 4. Betancourt JA, Rosenberg MA, Zevallos A, Brown JR, Mileski M. The impact of COVID-19 on telemedicine utilization across multiple service lines in the United States. Healthcare (Basel) 2020;8:380.
- 5. Taylor MW. Vaccines against viral infections. In: Taylor MW, editor. Viruses and man: a history of interactions. Cham: Springer; 2014. p. 355-77.
- 6. Bloom BR, Nowak GJ, Orenstein W. "When will we have a

# Osman Samet Gunkaya et al • Attitude of pregnant women to COVID-19 vaccine

- vaccine?": understanding questions and answers about COVID-19 vaccination. N Engl J Med 2020;383:2202-4.
- 7. World Health Organization. Ten threats to global health in 2019 [Internet]. Geneva: World Health Organization; 2019 [cited 2023 Mar 10]. Available from: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
- 8. Wiysonge CS, Ndwandwe D, Ryan J, et al. Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future? Hum Vaccin Immunother 2022;18: 1-3.
- Favre G, Pomar L, Baud D. Coronavirus disease 2019 during pregnancy: do not underestimate the risk of maternal adverse outcomes. Am J Obstet Gynecol MFM 2020;2: 100160.
- 10. Jering KS, Claggett BL, Cunningham JW, et al. Clinical characteristics and outcomes of hospitalized women giving birth with and without COVID-19. JAMA Intern Med 2021;181:714-7.
- 11. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020;370:m3320.
- 12. Khalil A, Kalafat E, Benlioglu C, et al. SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis of clinical features and pregnancy outcomes. EClinicalMedicine 2020;25:100446.
- 13 Martinez-Perez O, Vouga M, Cruz Melguizo S, et al. Association between mode of delivery among pregnant women with COVID-19 and maternal and neonatal outcomes in Spain. JAMA 2020;324:296-9.
- 14. Baud D, Greub G, Favre G, et al. Second-trimester miscarriage in a pregnant woman with SARS-CoV-2 infection. JAMA 2020;323:2198-200.
- 15. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons. N Engl J Med 2021;384:2273-82.
- Dagan N, Barda N, Biron-Shental T, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med 2021;27:1693-5.
- 17. Januszek SM, Faryniak-Zuzak A, Barnas E, et al. The approach of pregnant women to vaccination based on a COVID-19 systematic review. Medicina (Kaunas) 2021;57: 977.
- 18. Pulatoglu C, Turan G. Women's knowledge and beliefs towards vaccination for influenza during pregnancy in Tur-

- key and underlying factors of misinformation: a singlecentre cross-sectional study. Cent Eur J Public Health 2020;28:124-9.
- 19. Cunningham RM, Minard CG, Guffey D, Swaim LS, Opel DJ, Boom JA. Prevalence of vaccine hesitancy among expectant mothers in Houston, Texas. Acad Pediatr 2018;18: 154-60.
- 20. Mohd Azizi FS, Kew Y, Moy FM. Vaccine hesitancy among parents in a multi-ethnic country, Malaysia. Vaccine 2017; 35:2955-61.
- 21. Sumbuloglu V, Sumbuloglu K. Sampling methods and sampling size in clinical and field research. Ankara: Hatiboglu Yayinevi; 2005.
- 22. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine: United States, December 2020. MMWR Morb Mortal Wkly Rep 2020;69:1922-4.
- 23. LaCourse S, John-Stewart G, Adams Waldorf KM. Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials. Clin Infect Dis 2020;71: 879-81.
- 24. Volkov S; World Health Organization. Ten threats to global health in 2019: vaccine hesitancy [Internet]. Geneva: World Health Organization; 2019 [cited 2023 Mar 10]. Available from: https://www.who.int/news-room/spotlight/tenthreats-to-global-health-in-2019
- 25. Riley LE, Beigi R, Jamieson DJ, et al. COVID-19 vaccination considerations for obstetric-gynecologic care [Internet]. Washington (DC): American College of Obstetricians and Gynecologists; 2020 [cited 2023 Mar 10]. Available from: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-against-covid-19
- 26. Society for Maternal-Fetal Medicine. Society for Maternal-Fetal Medicine (SMFM) statement: SARS-CoV-2 vaccination in pregnancy [Internet]. Washington (DC): Society for Maternal-Fetal Medicine; 2020 [cited 2023 Mar 10]. Available from: https://s3.amazonaws.com/cdn.smfm. org/media/2591/SMFM\_Vaccine\_Statement\_12-1-20\_(final).pdf
- 27. Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 2021;27:225-8.
- 28. Skirrow H, Barnett S, Bell S, et al. Women's views on accepting COVID-19 vaccination during and after pregnan-

# CLINICAL AND EXPERIMENTAL VACCINE RESEARCH

Osman Samet Gunkaya et al • Attitude of pregnant women to COVID-19 vaccine

- cy, and for their babies: a multi-methods study in the UK. BMC Pregnancy Childbirth 2022;22:33.
- 29. Harrison EA, Wu JW. Vaccine confidence in the time of COVID-19. Eur J Epidemiol 2020;35:325-30.
- 30. Tsai FJ, Yang HW, Lin CP, Liu JZ. Acceptability of COV-ID-19 vaccines and protective behavior among adults in taiwan: associations between risk perception and willing-
- ness to vaccinate against COVID-19. Int J Environ Res Public Health 2021;18:5579.
- 31. Hosokawa Y, Okawa S, Hori A, et al. The prevalence of COVID-19 vaccination and vaccine hesitancy in pregnant women: an internet-based cross-sectional study in Japan. J Epidemiol 2022;32:188-94.